Peripheral Blood Stem Cells for T Cell–Replete Nonmyeloablative Hematopoietic Transplants Using Post-Transplant Cyclophosphamide  by Bashey, Asad
A. Bashey / Biol Blood Marrow Transplant 20 (2014) 597e599598different patients in different countries and with a different
brand of rabbit ATGdwould both come to exactly the same
protective effect on GVHD. Survival was also quite similar in
the twostudies, furtherconﬁrming that theprotective effectof
ATG on GVHD is not the result of a magic preparation, but
rather of downregulation of host T cell function.
In conclusion, the report of the SFGM [6] adds further
evidence to the fact that ATG protects against GVHD without
a detrimental effect on relapse and survival. So why not use
ATG for all unrelated donor transplantations and perhaps
also for sibling peripheral blood grafts? If I were a patient,
ready to be admitted for an allogeneic transplantation, say, a
peripheral blood graft from an unrelated donor, I would be
aware of a signiﬁcant risk of acute and chronic GVHD, and I
would like to be protected as much as possible. ATG is
perhaps the best available choice, together with alemtuzu-
mab, to reduce the risk of GVHD morbidity.ACKNOWLEDGMENTS
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plants from HLA-haploidentical donors performed using
conventional pharmacologic graft-versus-host disease
(GVHD) prophylaxis (eg, calcineurin antagonist and meth-
otrexate) were largely unsuccessful because of severe post-
transplant alloreactivity [1,2]. More successful strategies for
transplants from haplodentical donors have included
extensive ex vivo and/or in vivo T cell depletion [3-5], ormore recently, T cellereplete grafts using post-transplant
cyclophosphamide (ptCy) to control alloreactivity [6-9].
Whereas mobilized donor peripheral blood stem cells
(PBSC) have been the preferred graft source for strategies
that involve T cell depletion, unmobilized donor marrow
has been the graft source with T cellereplete transplants
utilizing ptCy. The reasons behind a preference for bone
marrow grafts in studies of T cellereplete haploidentical
transplants using ptCy are complex. They include the pio-
neering work in this ﬁeld at Johns Hopkins University,
where unmobilized bone marrow (BM) is the institutionally
preferred graft source for almost all transplants, and con-
cerns that the larger number of T cells typically present in
granulocyte-colony stimulating factore (G-CSF) mobilized
PBSC may overwhelm the ability of ptCy to suppress detri-
mental alloreactivity post-transplant.
However, several beneﬁts may be realized if mobilized
PBSC were shown to be safe in this setting. Speciﬁcally, the
scheduling challenges of bone marrow harvests in an era of
limited access to operating room and physician resources
A. Bashey / Biol Blood Marrow Transplant 20 (2014) 597e599 599may be ameliorated. The higher T cell dose associated
with PBSC may possibly result in stronger graft-versus-
malignancy effects for patients with advanced malignancies
(as has been seen in the setting of matched related donor
transplants), and donor preferences for avoiding general
anesthesia and autologous blood donation may be accom-
modated. Our group has previously demonstrated that G-CSF
mobilized PBSC can be safely and effectively utilized for
T cellereplete haploidentical donor transplantations when
used with myeloablative preparative regimens [9]. However,
the use of PBSC as the graft source with the most frequently
used preparative regimen for T cellereplete HLA-
haploidentical donor transplantation using ptCy, namely
the combination of ﬂudarabine, single (2Gy) fraction total
body irradiation, and pre- and post-transplant cyclophos-
phamide developed at Johns Hopkins University, has not
been widely reported. In this issue of Biology of Blood and
Marrow Transplantation, Castagna et al. [10] report on a
nonrandomized comparison of 23 T cellereplete hap-
loidentical donor transplants performed using ptCY and
using G-CSF mobilized PBSC, with 46 such transplants
contemporaneously performed using conventional BM
grafts. A preparative regimen very similar to the non-
myeloablative regimen developed at Johns Hopkins Univer-
sity was used for all patients. Median times to neutrophil and
platelet engraftment were 24 to 48 hours slower in the BM
patients, but the differences were not statistically signiﬁcant.
Similarly, no statistically signiﬁcant differences in rates of
acute and chronic GVHD, infection, nonrelapse mortality,
overall survival, and progression-free survival were seen
between the BM and PBSC patients. This study suggests that
G-CSF mobilized PBSC can safely be used as the graft source
for patients receiving a T cellereplete HLA-haploidentical
donor transplant using the nonmyeloablative preparative
regimen developed at Johns Hopkins University. However,
the equivalence of PBSC and BM cannot be established
without an adequately powered prospective randomized
comparison and several imbalances between the PBSC and
BM groups necessitate appropriate caution when interpret-
ing the results of this study by Castagna et al [10]. The PBSC
transplants were exclusively performed in one of the two
centers authoring this study, while the calcineurin antago-
nist and antifungal prophylaxis used were different between
the two centers. There were also differences between the
BM and PBSC patients with respect to age, frequency and
types of prior transplant, median hematopoietic cell trans-
plantationecomorbidity index score, and, importantly, in
median follow-up (332 days for PBSC versus 726 days for BM
patients). For example, one of the more important questions
is whether chronic GVHD incidence and severity would be
higher in patients transplanted with HLA-haploidentical
PBSC than with haploidentical marrow, as has been shown
for HLA-matched donors. Whereas no signiﬁcant difference
in chronic GVHD incidence was found in this study, theshorter median follow-up for PBSC patients limits the
effectiveness of this comparison. Furthermore, the relatively
small number of PBSC patients impairs the statistical power
of the comparison in outcome measures. For example, non-
relapse mortality was 12% in PBSC patients versus 22% in BM
patients, and BK virus hemorrhagic cystitis occurred in 0%
versus 11%, respectively, but these differences were not
statistically signiﬁcant.
Despite these limitations, this study provides the ﬁrst
published evidence that PBSC can safely be used with
the nonmyeloablative regimen developed by Johns Hop-
kins University investigators for T cellereplete HLA-hap-
loidentical transplantation and will help widen the options
available to centers and donors where such trans-
plantation is performed.ACKNOWLEDGMENTS
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